Zimmer has announced that it has appointed Paul Bisaro, chairman, president and chief executive officer of Actavis, to its board of directors. Bisaro has served as president and chief executive officer and a member of the board of directors of Actavis (formerly Watson Pharmaceuticals) since 2007. He was appointed chairman in October 2013 following the company’s acquisition of Warner Chilcott. During Bisaro’s tenure as chief executive officer, the company’s revenues have grown from approximately US$2 billion to anticipated pro forma revenue of approximately US$11 billion in 2013.
“Paul Bisaro brings a wealth of experience leading highly respected global pharmaceutical companies and a strong track record of growth and international expansion; his perspective as a healthcare industry veteran will be instrumental to Zimmer’s board of directors,” said Larry Glasscock, chairman of the board. “We are delighted that Paul has agreed to join the board and we look forward to his contribution in guiding Zimmer’s long-term strategic vision.”
Bisaro holds a Juris Doctor from The Catholic University of America in Washington, DC, USA, and earned his undergraduate degree in general studies at the University of Michigan. He currently serves on the board of visitors of The Catholic University of America, Columbus School of Law.